We are currently investigating CCDC6 behavior in BRCA WT patients with newly diagnosed advanced epithelial ovarian cancer who achieved a partial or complete response to first-line platinum-based chemotherapy and are enrolled in the multicenter, prospective, single-arm MITO35A trial of olaparib maintenance therapy. The gene discussed is CCDC6; the disease is ovarian carcinoma.